INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $263,377 | +3.5% | 5,057 | +25.8% | 0.00% | – |
| Q2 2023 | $254,408 | +32.0% | 4,020 | +13.0% | 0.00% | – |
| Q1 2023 | $192,786 | +16.1% | 3,559 | +14.3% | 0.00% | – |
| Q4 2022 | $166,000 | +7.8% | 3,114 | -5.9% | 0.00% | – |
| Q3 2022 | $154,000 | -84.1% | 3,308 | -80.5% | 0.00% | -100.0% |
| Q2 2022 | $966,000 | -35.8% | 16,932 | -31.1% | 0.00% | -33.3% |
| Q1 2022 | $1,504,000 | +1734.1% | 24,585 | +1467.9% | 0.00% | – |
| Q4 2021 | $82,000 | +127.8% | 1,568 | +63.3% | 0.00% | – |
| Q3 2021 | $36,000 | -20.0% | 960 | -13.2% | 0.00% | – |
| Q2 2021 | $45,000 | +87.5% | 1,106 | +55.6% | 0.00% | – |
| Q1 2021 | $24,000 | +4.3% | 711 | -3.4% | 0.00% | – |
| Q4 2020 | $23,000 | +4.5% | 736 | -13.7% | 0.00% | – |
| Q3 2020 | $22,000 | -63.3% | 853 | -63.9% | 0.00% | – |
| Q2 2020 | $60,000 | +81.8% | 2,363 | +9.9% | 0.00% | – |
| Q1 2020 | $33,000 | – | 2,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |